



HCV in frequent blood recipients



By Dr Masood Ziaee

Professor of Infectious Disease







Hepatitis C in Hemodialysis









- > Patients with ESRD on hemodialysis (HD) are at greater risk of acquiring HCV :
- ✓ permanent vascular access
- ✓ frequent exposure to possibly contaminated medical equipments.
- Hepatitis C virus is a major cause of liver disease among chronic renal failure patients undergoing maintenance hemodialysis.

Mostafa Alavi-Moghaddam*, MD, MPH, AFSA



Epidemiology of HepC in HD




- The prevalence of HCV infection among dialysis patients varies markedly from country to country
- Ranging from 3% in North-western Europe (the Netherlands) to more than 76% in South East Asia (Indonesia)
- There is also a wide variation among dialysis centers within a single country.

Mostafa Alavi-Moghaddam*, MD, MPH, AFSA





Epidemiology of HCV Infection among hemodialysis patients in countries of EMRO



Alavian SM, et al. Epidemiology and risk factors of HCV infection among hemodialysis patients in countries of the Eastern Mediterranean Regional Office of WHO (EMRO): a quantitative review of literature. J Public Health (Oxf). 2011.





Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions

M. HARFOUCHE¹, H. CHEMAITELLY¹, S. MAHMUD¹, K. CHAABNA^{1,2}, S. P. KOUYOUMJIAN¹, Z. AL KANAANI¹ and L. J. ABU-RADDAD^{1,2}*

¹Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar ²Department of Healthcare Policy & Research, Weill Cornell Medicine, Cornell University, New York, USA

Received 7 June 2017; Final revision 14 August 2017; Accepted 6 September 2017



. Pooled mean estimate for hepatitis C virus (HCV) antibody prevalence among hemodialysis patients across countries of the Middle East and North

Africa

	Stadias	Generales	HCV Prevale across studies				Heterogeneity measures		
Country	Studies Total N	Samples Total N	Range (%)	Median	Mean (%)	95% CI	$Q^{\rm a}$ (<i>P</i> -value)	<i>I</i> ^{2b} (95% CI)	Prediction interval ^c (%)
Algeria	3	4101	22.8-42.0	23.8	29.3	17.4-42.7	$133.7 \ (P < 0.0001)$	98.5 (97.4–99.1)	0.0-100
Fgynt	26	4915	10.0-100	69.0	65.5	56.5-74.1	$809.1 \ (P < 0.0001)$	96.9 (96.2–97.5)	18.9–98.6
Iran	41	15 140	$0 - 31 \cdot 4$	8.5	9.2	5.9-10.8	$1076 \cdot 5 \ (P < 0.0001)$	96.3 (95.6–96.9)	0.0-29.4
Iraq	16	1353	0–42·9	14.3	16.6	9.0 - 25.7	$248 \cdot 2 \ (P < 0.0001)$	94.0 (91.6–95.6)	0.0-62.1
Jordan	9	2730	20.5 - 59.5	32.5	36.1	27.4-45.2	$120.7 \ (P < 0.0001)$	93.4 (89.5–95.8)	9.0-69.1
Kuwait	3	1597	4.7 - 40.0	8.2	14.9	$2 \cdot 8 - 34 \cdot 1$	$155.8 \ (P < 0.0001)$	98.7 (97.8–99.2)	0.0-100
Lebanon	9	4214	$0 - 27 \cdot 0$	5.6	7.3	3.7 - 11.7	$159.0 \ (P < 0.0001)$	95.0 (92.3–96.7)	0.0-27.1
Libya	5	3559	12.0-42.5	21.0	22.5	14.2-31.9	$95.1 \ (P < 0.0001)$	95.8 (92.7–97.6)	0.6 - 61.2
Morocco	7	1387	8.0-76.0	49.0	46.4	$28 \cdot 5 - 64 \cdot 7$	239.4 (P < 0.0001)	97.5 (96.3–98.3)	0.2 - 98.1
Pakistan	7	995	16·4–68·0	28.0	30.4	21.7-39.9	$49.4 \ (P < 0.0001)$	87.8 (77.3–93.5)	5.7 - 63.5
Palestine	12	1260	7.9_41.4	X•()	10.3	$5 \cdot 6 - 16 \cdot 2$	$93.8 \ (P < 0.0001)$	88.3 (81.4–92.6)	0.0-36.8
Saudi Arabia	39	43 250	18.9 - 78.2	46.9	47.4	43.7-51.1	998.1 ($P < 0.0001$)	96.2 (95.5–96.8)	26.8-68.4
Sudan	3	635	8.5–34.9	23.7	20.4	7.6 - 37.2	36.4 (P < 0.0001)	94.5 (87.3–97.6)	0.0-100
Syria	5	809	$42 \cdot 4 - 75 \cdot 0$	53.9	56.6	47.5-65.5	$24.2 \ (P < 0.0001)$	83.5 (62.6–92.7)	24.7-85.7
Tunisia	14	5602	14.6-46.5	29.8	27.4	$22 \cdot 6 - 32 \cdot 5$	$194.4 \ (P < 0.0001)$	93.3 (90.4–95.3)	10.3 - 48.9
Yemen	3	300	40.0-62.7	40.2	47.4	32.7-62.3	8.6 (P = 0.010)	76.8 (24.2–92.9)	0.0-100
Oman	1	102	_	_	26.5	$18 \cdot 2 - 36 \cdot 1$	_	_	_
Qatar	1	130	_	_	44.6	35.9-53.6	_	_	_
UAE	1	262	_	_	24.4	19.3-30.1	_	_	_
Pooled HCV prevalence stratified by temporal duration									
1989–1998	50	8964	15.7 - 100	46.5	51.6	46.1-57.1	$1235 \cdot 3 \ (P < 0.0001)$	96.0 (95.4–96.6)	16.0-86.3
1999–2008	69	53 500	0.0-78.5	23.8	27.8	23.1-32.8	7325.6 (P < 0.0001)	99.1 (99.0–99.1)	0.8 - 71.6
2009–2016	86	29 877	0.0 - 94.1	9.7	18.8	14.5-23.5	$7941 \cdot 1 \ (P < 0.0001)$	98.9 (98.8–99.0)	0.0-68.8
All countries	205	92 341	0-100	26.5	29.2	25.6-32.8	$26145\cdot 8 \ (P < 0.0001)$	99.2 (99.2–99.3)	0.0 - 82.0





Pooled mean estimate for hepatitis C virus (HCV) viremic rate among hemodialysis patients across countries of the Middle East and North Africa. HCV viremic rate is the prevalence of HCV chronic infection (HCV RNA positivity) among antibody-positive persons

			HCV RNA prevalence among antibody positive persons		Pooled HCV viremic rate		Heterogeneity measures			
Country	Studies Total N	Samples Total N	Range (%)	Median	Mean (%)	95% CI	$Q^{\rm a}$ (<i>P</i> -value)	<i>I</i> ^{2b} (95% CI)	Prediction interval ^c (%)	
Iran	4	219	48.6-64.3	52.3	51.1	44.3-57.9	$1.3 \ (P = 0.7)$	0.0 (0.0-65.0)	36.4-68.8	
Iraq	2	144	26.1-61.5	43.8	38.9	30.9-47.4	_	_	_	
Jordan	1	92	_	_	31.5	$22 \cdot 2 - 42 \cdot 0$	_	_	_	
Lebanon	2	63	30.4-65.0	47.7	39.7	$27 \cdot 6 - 52 \cdot 8$	_	_	_	
Libya	1	32	_	_	72.0	53.2-86.2	_	_	_	
Morocco	4	309	$48 \cdot 9 - 70 \cdot 0$	59.7	57.9	49.2-66.5	5.3 (P = 0.1)	43.5 (0.0-81.1)	27.0-85.9	
Pakistan	1	25		_	28.0	12.1-49.4	_	_	_	
Palestine	2	290	19.1–84.1	51.6	29.0	$28 \cdot 8 - 34 \cdot 5$	_	_	_	
Syria	1	56	_	_	87.5	75.9–94.8	_	_	_	
Tunisia	13	1942	51.0-93.3	76.2	75.1	69.6-80.2	$61.9 \ (P < 0.0001)$	80.6 (67.8-88.3)	54.6–91.1	
All countries	31	3172	19.1–93.3	65.4	63.0	55.4-70.3	$499.9 \ (P < 0.0001)$	94.0 (92.4–95.2)	21.7–95.5	

HCV, Hepatitis C virus; RNA, Ribonucleic acid.

^a Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in effect size. ^b I^2 : A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.

^c Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.



Frequency, distribution, and Shannon Diversity Index of hepatitis C virus (HCV) genotypes among hemodic North Africa

Country	Studies Total <i>N</i>	Samples Total <i>N</i>	Genotype 1 n (%)	Genotype 2 n (%)	Genotype 3 n (%)	Genotype 4 <i>n</i> (%)
Bahrain	1	9	5 (55.5%)	3 (33·3%)	_	1 (11.1%)
Egypt	1	62	10 (16.1%)	_	_	52 (83.9%)
Iran	7	269	150 (55.7%)	—	106 (39·4%)	13 (4.8%)
Iraq	2	33	17 (51.5%)	_	1 (3%)	15 (45.4%)
Jordan	1	30	22 (73.3%)	_	_	8 (26.6%)
Lebanon	4	64	18 (28.1%)	16 (25%)	4 (6.2%)	26 (40.6%)
Morocco	2	68	68 (100%)	_	_	_
Pakistan	1	90	20 (22.2%)	12 (13·3%)	56 (62·2%)	2 (2·2%)
Saudi Arabia	1	32	15 (46.8%)	1 (3.1%)	—	16 (50.0%)
Syria	1	28	17 (60.7%)	_	_	11 (39.3%)
Tunisia	10	1529	1182 (77.3%)	181 (11.8%)	10 (1%)	156 (10.0%)
All countries (unweighted)	31	2214 ^b	1524 (68.8%)	213 (9.6%)	177 (7.9%)	300 (13.5%)
All countries (weighted by population size)	31	2214 ^b	1524 (39.3%)	213 (5.7%)	177 (29.6%)	300 (25.4%)

No data were found for HCV genotypes 5, 6, and 7.



Hepatitis C virus (HCV) epidemiology among hemodialysis (HD)patients in the Middle East and North Africa (MENA).



The regional pooled mean estimate was

- ✓ 29·2% (95% CI: 25·6–32·8%) for HCV antibody positive prevalence
- ✓ 63.0% (95% CI: 55.4–70.3%) for the viremic rate.

>Genotype diversity :

- ✓ genotype 1 (39·3%)
- ✓ genotype 2 (5·7%)
- ✓ genotype 3 (29·6
- ✓ genotype 4 (25·4%).







Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis

World J Gastroenterol. 2017 Jan 7; 23(1): 151–166 Soheil Ashkani-Esfahani, Seyed Moayed Alavian, and Mohammad Salehi-Marzijarani

The overall HCV infection prevalence among hemodialysis patients in the region was reported to be 25.3%


Egypt-50% and Syria -54% had the highest reported rates while Iran -12% and Lebanon -9% had the lowest.



The prevalence of HCV infection among different HD patients among Iranian population

Fig. 2 Geographical distribution of HCV infection in hemodialysis patients in Iran






HCV infection varies widely between 5.5% and 24% among different HD patients


Alavian SM, et al . J Public Health. .2010





Seroprevalence of Blood born disease in Hemodialysis patients of South Khorasan province





Bangladesh Journal of Medical Science Vol. 13 No. 01 January'14

Original article:

008

Prevalence of HCV Infection in Hemodialysis Patients of South Khorasan in Comparison With HBV, HDV, HTLV I/II, And HIV Infection

Ziaee M¹, Azizee R², Namaei MH³*

<u>Abstract:</u>

Background and objective: This study was performed to evaluate the prevalence of Hepatitis C virus (HCV) infection as well as HBV, HDV, HTLV I/II, and HIV infection in hemodialysis patients in our district.

Methods: The subjects of this study involved 41 hemodialysis patients admitted to hemodialysis ward, Vali- Asr hospital. HBV, HDV, HIV, and HTLV1/2 infections were evaluated by enzyme-linked immunosorbent assay (ELISA) technique. Serum anti- HCV anti-body was measured using the 3rd generation of ELISA kit. HCV Viremia was evaluated in all patients using RT-PCR technique.

Results: HCV infection was not observed in none of patients by ELISA technique; however RT-PCR technique demonstrated HCV viremia in one (2.43%) patient. HBsAg was detected in 4(9.75%) patients, and one (2.43%) was Anti HTLV 1/2 positive; none of patients were HDV or HIV positive.

Conclusion: HCV infection is less common than HBV infection in our patients. ELISA technique can not demonstrate all hemodialysis patients with HCV infection, For this reason it is requirement to evaluate this group of patients for HCV infection using RT-PC technique.

Keywords: Hemodialysis, Hepatitis C, Hepatitis B, HIV Infections, HTLV I/II Infections

DOI: http://dx.doi.org/10.3329/bjms.v13i1.13903 Bangladesh Journal of Medical Science Vol. 13 No. 01 January '14 Page 36-39



Risk factors for acquiring HCV infection among patients undergoing HD



- 1-long hemodialysis duration
- 2-Three or more HD sessions per week
- 3-Male gender
- 4-Old age
- 5 -Previous blood transfusion



Patients with Renal Impairment




- HCV is independently associated with the development of chronic kidney disease (CKD) (<u>Rogal, 2016</u>);
- A meta-analysis published in 2015 demonstrated that chronic HCV infection was associated with
- \checkmark 51% increase in the risk of proteinuria
- ✓ 43% increase in the incidence of CKD (Fabrizi, 2015).
- ✓ There is also a higher risk of progression to end-stage renal disease (ESRD) in persons with chronic HCV and CKD,
- ✓ Increased risk of all-cause mortality in persons on dialysis (Lee, 2014); (Fabrizi, 2012).



Harmful long-term impact of hepatitis C virus inf in kidney transplant recipients

Most renal transplant recipients (RTRs) have acquired HCV infection prior totransplantation

Romero E, et al. Transplant Proc. 2008;40(9):2933-5



Months after RT

Legendre C, et al. Transplantation 1998 Mar 15;65(5):667-70

Mostafa Alavi-Moghaddam*, MD, MPH, AFSA





- 1-Implementing more sensitive screening methods to detect HCV;
- 2-Treatment of all hemodialysis patients with HCV infection
- 3-Reducing the duration of the hemodialysis period by early transplantation.
- 4-Education of nurses in HD Centers: Infection Control -policies

5-Minimizing transfusion requirements by the judicious use of erythropoietin.

Alavian SM., CRF Control is Possible! Hepat Mon. 2006;6(2

Mostafa Alavi-Moghaddam*, MD, MPH, AFSA





Treatment of HCV ^{**} infection in Hemodialysis



RATIONALE FOR ANTIVIRAL TREATMENT



- The main reason for antiviral treatment in patients with chronic HCV infection is :
- ✓ prevent *liver complications*(liver-associated morbidity and mortality)
- ✓ In the patient with kidney transplant candidate, prevent kidney transplant-related complications specific to HCV infection.
- ✓ In the less common scenario of *HCV related vasculitis* and/or glomerulonephritis (such as mixed cryoglobulinemia),





REGIMEN SELECTION



Major progress has been made over the last 2 decades.



- Sustained viral response (SVR) rates increased progressively:
- \checkmark 7 to 10% with interferon alone,
- \checkmark 25% with interferon and ribavirin,
- \checkmark 40-50% with peginterferon and ribavirin.
- ✓ to >95% with the current direct-acting antiviral agents (DAAs).



Direct-acting antiviral agents



Among the currently approved DAAs, sofosbuvir is the only one that has significant renal elimination.

- ➤The other currently approved DAAs –
- ✓ simeprevir,
- ✓ ledipasvir,
- ✓ daclatasvir,
- ✓ paritaprevir/ritonavir,

- ✓ ombitasvir,
- ✓ dasabuvir,
- ✓ Grazoprevir
- ✓ elbasvir
- Are not eliminated by the kidneys and thus do not need dose adjustment, even in severe CKD or in hemodialysis (HD) patients.



The decision to treat HCV in patients with renal impairment



- Made on a <u>case by case basis</u>.
- Treat HCV based on the potential benefits and risks of therapy, including:
 - ✓ Life expectancy
 - \checkmark Candidacy for kidney transplantation
 - ✓ Comorbidities such as cardiovascular disease
- Multiple host factors contribute to this decision, including :
- ✓ Extent of renal impairment,
- ✓ The extent of liver disease
- \checkmark The presence of comorbidities that affect the potential toxicity of antiviral therapy.
- ✓ The genotype,
- ✓ History of past antiviral treatment.



Renal function estimation of CrCl or GFR



Based on the estimated CrCl or GFR value, patients with renal impairment are classified as having

✓ Mild (50 to 80 mL/min)

✓ Moderate (30 to 50 mL/min)

✓ Severe (less than 30 mL/min)



For patients with mild renal impairment(50 to 80 mL/min)



• No dose adjustments are needed for any of the medications used to treat HCV.

Treatment of Hepatitis C in Patients with Renal Impairment

© https://www.hepatitisc.uw.edu October 10, 2017

For patients with moderate renal impairment(30 to 50 mL/min)



Standard doses are recommended for the direct-acting antiviral agents and peg interferon alfa-2a.

✓ Peginterferon alfa-2b requires a 25%

000

✓ Dose reduction :Ribavirin doses should be reduced to a schedule of 200 mg alternating with 400 mg every other day.





Recommendations for Patients With CKD Stage^a 1, 2, or 3

RECOMMENDED

No dose adjustment is required when using:

- Daclatasvir (60 mg)^b
- Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)
- Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)^c
- Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
- Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
- Simeprevir (150 mg)
- Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/ voxilaprevir (100 mg)
- Sofosbuvir (400 mg)



For patients with severe renal impairment(less than 30 mL/min)



- Although DAA-based regimens are feasible for many patients with severe renal impairment
- HCV antiviral therapy to those who are most likely to benefit from it in the short term.
- These include patients with *advanced fibrosis or cirrhosis*,
- ✓ patients who are *renal transplant candidates,*
- Those with significant HCV related kidney disease from
 mixed cryoglobulinemic vasculitis, and HCV-related glomerulonephritis.
- For patients with vasculitis and/or glomerulonephritis that warrant immunosuppressive therapy





The choice of the regimen



> The choice of the regimen should be based on :

- ✓ HCV Genotype (and subtype),
- ✓ viral load,
- ✓ Concomitant medications,
- ✓ kidney function,
- ✓ transplant candidacy,
- ✓ comorbidities.

Review - Advances in CKD 2017 Hepatitis C Treatment in Chronic Kidney Disease Patients:

Dr.

For patients with severe renal impairment



- Data on the safety direct-acting antivirals (DAAs) in the setting of severe renal impairment or dialysis (hemodialysis or peritoneal dialysis) are evolving.
- Given the significant potential for *adverse effects* with the combination of peginterferon and <u>ribavirin</u>,
- We favor utilizing an *interferon-free*, combination DAA-based regimen in these patients. For all patients with severe renal impairment,
- decisions to provide these patients with HCV treatment should be undertaken on a case-by-case basis.
- We prefer the pangenotypic DAA regimen of *Glecaprevir-Pibrentasvir*





Duration of Treatment



UpToDate[®] 2017

The duration of *Glecaprevir-Pibrentasvir* for patients with renal impairment is the same for those with normal renal function and depends on the presence of *cirrhosis* and *treatment history*.

For treatment-naïve patients of any genotype, it is given for 8 weeks for those without cirrhosis and 12 weeks for those with compensated cirrhosis.

• *Glecaprevir-Pibrentasvir* is contraindicated in patients with decompensated cirrhosis (Child Pugh class B or C).





Recommended regimens listed by evidence level and alphabetically for: Patients With CKD Stage^a 4 or 5 (eGFR <30 mL/min or End-Stage Renal Disease)

RECOMMENDED	GENOTYPE	DURATION	RATING 🕄
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	1a, 1b, 4	12 weeks	I, B
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b	1, 2, 3, 4, 5, 6	8 to 16 weeks ^c	I, B ^c



For patients with severe renal impairment



- Including those with end-stage renal disease,
- ✓ The peginterferon alfa-2a dose should be reduced to 135 mcg per week;
- \checkmark The peginterferon alfa-2b requires a 50% dose reduction .
- ✓ Adjustments are needed for any of the medications used to treat HCV.
- ✓ The recommended ribavirin dose is 200 mg/day
- Caution should be exerted when using ribavirin in patients with renal failure because of the risk of *severe hemolysis*.
- Ribavirin should be *discontinued* if the hemoglobin level decreases by more than
 2 g/dL despite the use of erythropoietin.



A LORCE

For patients with acute vasculitic manifestations associated with HCV infection:

Immunosuppressive therapy first and delay antiviral therapy for one to four months.

For patients who are expected to require kidney transplant and are candidates for antiviral therapy:

- ✓ We initiate antiviral therapy so that it is completed prior to kidney transplantation if possible.
- However, kidney transplantation should not be prohibited in untreated HCVinfected patients without advanced fibrosis, as patients can receive effective interferon-free HCV treatment post transplantation.





Hepatitis C in Hemophililic patients






Epidemiology of HCV Infection in Hemophilia in Iran



- Seroprevalence of HCV infection among hemophilia patients in Iran:
- ✓ Varies from 13.3% to 80.5 %
- ✓ The pooled estimation was 48.07%.
- > The lowest rate: Fasa with 13.3%
- The highest rate : Isfahan with 80.5%
- South Khorasan province: 20%
- We found that prevalence of HCV infection among hemophilia patients is significantly lower in south of Iran versus north and central parts of Iran

Alavian SM, et al. Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis. Hepat Mon. 2012

The prevalence of HTLV-1 and its Co-Infection withHCV, HBV and HIV in Hemophilic patients Masoud Ziaee, Mohammad Hassan Namaei, Ghodseh Azarkar



BILLE C



PAKISTAN JOURNAL OF MEDICAL SCIENCES Bi-Monthly

Current

Advertising

Archives

Home > Vol 31, No 5 (2015) > **Ziaee**

About

The prevalence of HTLV-1 and its Co-Infection with HCV, HBV and HIV in Hemophilic patients

Masoud Ziaee, Mohammad Hassan Namaei, Ghodseh Azarkar

Abstract

Home

Background and Objective: Blood-borne infections, such as the HIV virus and hepatitis B and C, are major problems in patients receiving blood products. Here we examined the prevalence of HTLV-1, HCV, HBV, and HIV in hemophilic patients.

Methods: A cross-sectional study on 108 hemophilic patients (101 males and 7 females) involved detection of HBV, HCV, HIV and HTLV-1 infections using immunoassays for HBsAg, hepatitis B core antibodies (anti-HBc), hepatitis C antibodies (anti-HCV), HIV antibodies (anti-HIV) and Anti-HTLV-1. Real-time PCR was used to measure HCV RNA, and HCV genotyping was performed by direct sequencing of the 5' noncoding region.

Results: Hemophilia A was reported in 93 (86%) patients with severe symptoms in 8 cases. The seroprevalence of anti-HCV and anti-HTLV-1 antibodies was 20% and 3% respectively. One patient with severe hemophilia had a HCV/HTLV-1 co-infection. HCV-RNA was detected in 82% of patients. In terms of genotyping prevalence was 56% HCV genotype 3a, 39% HCV genotype 1a, and 6% HCV genotype2. Anti HIV and HBsAg were not detected in any patient. HTLV1 prevalence was higher, HCV lower in South Khorasan than other regions in Iran or elsewhere.

Conclusion: Management of transfusion of blood and blood products should account for the underlying prevalence of infectious agents.

doi: http://dx.doi.org/10.12669/pjms.315.7888

Liver International ISSN 1478-3223



CLINICAL STUDIES

Peginterferon α -2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases

Seyed-Moayed Alavian¹, Seyed Vahid Tabatabaei¹, Maryam Keshvari², Bita Behnava¹, Seyyed Mohammad Miri¹, Pegah Karimi Elizee² and Kamran Bagheri Lankarani³

We started elimination of HCV in hemophilia 10 years ago!!

Two hundred and twenty-five subjects **61%** achieved SVR, 66 patients relapsed and 30 subjects did not respond and nine patients developed breakthrough during treatment.

Peg interferon alpha-2a in combination with weight-based ribavirin has SVR rate of **51%** for genotype 1 and **71%** for genotype non-1 infections in hemophilia patients.

Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010;30(8):1173-80.

Wand Li Statistas; Sim At 11 Dr. All the company flows and the 2291 Sil Grow Star CAR, Hy Aller and in it in 17 NI 1, 18 and the fit with the the the aly state pay and At 1, 80. Cing the second and NO, H, W. is a particular in the and the and the the second and the second 25 stilling; In inter ay, 1, 1V - K. K. K. K. C. (124) . 20 - 17, 1, 6 1 20 701 401 - X01 000 - 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 19, 1, 19 in igen 1 18 in it and 100, 11, 12, Scholder in it is all 1,1,1, Seal (19/1) - 20 21 19,1,1 I speak the is a start to a start of the and the start of the and the Topological in the AVIY N Per 1 AT " INT " AD IT, & Schuldt in inter 19 the let way the first 10 (1 1 1 K) (1 K) (K) (K) (K) Cipecture a prise sur a No , 17, 7. > malshind in it, 17, 11 Culy stadling in all at 1 V) er 2 14 4 Niger 1 10 to 2 2 course to A B, 14, 6 > Col Bin and Start T, 114 - tok par, South al, 1/1 2 concerne a for george - AO, 14, 4 - Higgs is with the what it was in all the N, K, K. in a set of the second of the The of allines; My X, Y? it is the set of the gest per 1 - 10, 11, 1 - out all series in the series of Job Kill in 17 Cille NY, Y, YF I share the service of the service o Caleborery Silver 1, 1, 1/4 in igner 1,2 " " I get the 1 " " A 1/1 por ser ser & Catholit 2001 - 2 at 17, 5, 59 I've inter the state of the and the state of the same with To by the opening i give at , 5, 4% in ignacing a wigener in the same the same in the same is the state of the state of the at 15, 5 is get 1,98 10 Clight 18 10 All 19 9 The and I Sty FM - white 4 biers - Int at, r, a no igen 1 48 10 migar 14 1 13/ 13/ 2 How we in 19 19 -Lotok Bur Verstin in igen 1, 28 11 part of the 12 All and all in it is in the Cul should in charts at, t, a MINIAN , " Mar say and in his case 29-Jan-08 18:00

SUBH J. Port Stray Can I capet not per proper per put of the to I'm year a the said we that the said the 1 3 mar and the man with the state VYJJY VA IN THE STATE A VALLES Light a Repairing the phill 1000 or in we soft at at School HAR IN March 14 MA, MARKA in the wind an and the fit Pripa 198 11 May Engen 11 NY, 17, 41 the water again that a part of the م الم م م مر مور معرف مركم Stipper 19 11 for each " 11 NY, T', T' for in the set of the set of the tay ! i issist a 11,6 4 Talacia IT, T, Y, W W Y KI LE W W Y KI DE WY HI I W W W Day in Mar By and any sugget 11 not igor set a dy 10 1,7,8, W Y 8, 129 mg + Y 8, 1 29, 5, 1 for in a set of a star with " " الار معرف الت Hy Jes 10 Kor Dy 17 in get 1 1 1 1 and a set of the NY , the it ight sport of you and a E.YE. in you had I a . -- in iger setter of 14 in iget 199 1 in in cape 1,9 " 11 AY, E, M and capes not a for an to 11 Erto. and sarry In All is all and the splan The art of the service of the At, E, K it is a set the same and the set the ()(前1)4 and Jes per y الرد الم مور معرف من اللود محرف من Concepcity in the safe and the A for a I say I'M We age The Ell it is the set of the first of the NY, E, I I'm is an with a fe his a the the for in the the find gold you I'm 14, Cu Yeu and han a Yeu ser his and good of it is and good of a AY, C, V por iges with the iges of the Esty A. Lager المكرد م الفروه ورا المعلم م الملوز عمر م A 3, 7, NA 10 Yes and my 4 4 Kesen win بالم الم الم محمد المن على المعرو المعرف المن 1, 1, 1, 1, 1, Verlage in A & Care in AI, K, 9 Mill after say in a face safe and Be upor pathe pringer where the - It a stay and may a ten and · ابتا بلا الم ور العرف مي الا م ور معرف مي Referenter prisantinta on 5 6/10 + 1 4/1 20 mil 10/10 1/0 till get INY a frigger INY " NT, F, U we iges 18 1 wie can the oft EXC 11 Yac have have to Yach have in iner well in adigulat in NY 54 in you will for goo what off a call we we are and the way fill 1 2 2 4 W W and a marker and the server and the ser مرد ما ، فرقد بن الدار + is good the in interest The there is the section the section the sector 1980 w grand to of MA So you for the good of the State of the state of the first for the first of the state of the sta for you yet it we server 0,0 i care y & parting a particular and El 14 Contration when any the ۲۰۱۶ «۲۰۸۶» «۲۰۰۹» «۲۰۰۹» «۲۰۰۹» «۲۰۰۹» I sante politicas yet u 0, 1. No a The second a second a dir in station at a first at all any can 14 b v exter when a ton a the A Shart Hart a she she with DA I se with a garden 4 1 ٩ , ٥ ٣ ٦ ٧ كي الموق من ١١ ١ ١ ١ ١ ٥ and not a par garph of y · ارد ۲ ۲ رومی سرد ۱۰ ۲ ورد عور شر and you splan places to 9, 1 29-lan-08

EASL Recommendations on Treatment of Hepatitis C 2016

- **Progression to end-stage liver disease** in patients with haemophilia is similar to HCV positive individuals in the general population.
- Death from liver failure in HCV positive individuals is among the commonest causes of death in patients with inherited bleeding disorders.
- The management of chronic hepatitis C in haemophilia is similar to the non-haemophilic population and HCV DAAs are applicable to patients with hemophilia.





Hepatitis C in Thalassemia patients







Introduction

 Patients with thalassemia or other hemoglobinopathies were at greater risk of acquiring HCV infection as a consequence of repeated transfusions of blood, respectively, before the introduction of blood donor screening for hepatitis C.

 \sim

Epidemiology of HCV in Thalassemia


Iran


In Iran from a total of 5229 thalassemia subjects

Its Seroepidemiology ranged from 2 to 32%. Pooled HCV infection rate was 18%

EMRO

Pooled HCV infection rate was: 45% in Pakistan 63% in Saudi Arabia 69% in Egypt





Hepatitis C in thalassemia in Iran

Hepatitis C in thalassemia in EMRO



In Iran, blood donors screening for HCV infection started in 1996. The pooled OR of HCV infection rate for patients transfused before that date was OR=7.6 and this implies an increase in blood safety and more attention to health precautions in Iran

Treatment of hepatitis C virus infection in thalassemia

- The past, the use of Peg-Interferon (Peg-IFN) and ribavirin (RBV) in thalassemia patients with HCV infection was limited by *both IFN and RBV side effects*.
- In particular, RBV was associated with increase in blood transfusion requirements and consequent iron overload.

We should be aware about cardiac and therapy of HCV with DDAs

- Minimal changes in strain, size, and volume of left ventricle, and size of right ventricle may refer to needing more precise cardiac evaluations in these patients.
- More specialized echocardiographic evaluations are recommended for whom with history of *cardiac abnormalities, severe cardiac iron load*, and in case of *any cardiac adverse event* during DAA therapy in thalassemia patients.
- Available Sofosbuvir-based regimens for HCV treatment in Iran are safe for our chronic HCV-infected thalassemia patients and cause no permanent cardiac damage.

Interferon-based regimens

>Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β -thalasaemia major (β -TM) due to poor efficacy and tolerance.

EASL Recommendations on Treatment of Hepatitis C 2016


- Treatment has often been withheld in these patients because both pegylated IFN- α and ribavirin can *cause anaemia*.
- *Few trials* with antiviral therapy have been published in this population, but there is *no* reason to consider that HCV DAAs are specifically *contraindicated*.
- For instance, in the C-EDGE IBLD study, the fixed-dose combination of grazoprevir and elbasvir was administered for 12 weeks without ribavirin in patients with haemoglobinopathies infected with genotypes 1a, 1b or 4.
- **Sofosbuvir-based** studies in this group are in progress.

Thalassemia

Elimination of HCV infection in Iran will be in 2030 but in thalassemia and hemophilia is possible in 2020!



Solution



Work together More support for therapy More attention to blood safety More education the nurses

More education the nurses in thalassemia centers Increase the thalassemia patients awareness regarding the issue.

